about
AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs.Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability.Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in miceLenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activitySemaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.Semaphorins and tumor angiogenesis.Class 3 semaphorins in cardiovascular development.The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling.Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program.Erratum: Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling.Increased expression of alpha6 integrin in endothelial cells unveils a proangiogenic role for basement membrane.Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy.Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Tumor angiogenesis: methods to analyze tumor vasculature and vessel normalization in mouse models of cancer.Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages.α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis.Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategyA rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agentTherapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models
P50
Q34774624-697FB36E-9D4C-4CC7-8D06-3AC42E6DE32DQ35148379-3518432F-A5B4-4566-9046-15F1A7C6DC9BQ35751013-4E140608-69C6-42F8-B571-3AAE32B2381BQ35913662-ABE54833-B478-4D93-9735-2D6589CC9BD1Q36871777-DFB6FD54-6297-4608-8CE9-7C262937B827Q37403111-48C9C672-F879-4861-909D-3F1E18EA945AQ37407913-3616234C-F59F-4C24-8504-4AD97B56734CQ37509074-9EEEA568-98BA-40F2-8D04-094CBD220F90Q38901012-352310E6-4CD9-4DE6-8783-99C26009B298Q41003127-1379F812-57CF-4F3C-972F-4423CF5B22D0Q41491009-E277AFCA-ADBE-4096-9B65-25B8B2062081Q42142865-B3C939CF-7B5F-4582-864F-35611F51927FQ43008646-CEE5A697-DCA8-4667-B276-7DE86424B941Q47094032-E726D2C0-DFCF-4718-9EBC-D8CF9E6362BFQ48970381-BAAC1A17-C8D3-4348-8267-D35BDE109DADQ49551908-690F7B3F-7F03-4FA1-87B6-3F2222743E05Q50217971-43A9981B-01AB-4E35-B177-81C04F2E8CD5Q53512280-DBFA9629-9B31-4271-8A03-2666CBDB9E47Q54521757-DE5A62C7-2C35-4095-990A-308A5704B460Q64933577-FBDA41CE-2AC4-437D-8AF3-9BBE38EB188EQ88467955-5A9665F1-CF3C-45D3-855C-CEA849ED7F12Q88792829-A1092BE0-954B-4B5E-84DD-568DE8FA6078Q89180454-DA213B2B-653E-44A0-B875-E1C8F1BC9142
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Federica Maione
@ast
Federica Maione
@en
Federica Maione
@es
Federica Maione
@nl
Federica Maione
@sl
type
label
Federica Maione
@ast
Federica Maione
@en
Federica Maione
@es
Federica Maione
@nl
Federica Maione
@sl
prefLabel
Federica Maione
@ast
Federica Maione
@en
Federica Maione
@es
Federica Maione
@nl
Federica Maione
@sl
P1053
K-6679-2016
P106
P21
P31
P3829
P496
0000-0003-2789-799X